Loading
A phase 3 trial of Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., active and no longer recruiting.
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations is a phase 3 interventional study registered as NCT04923906 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 624 participants planned, started 2021-08-11 and due to reach its primary completion in 2024-06-18. Interventions recorded: Aumolertinib, Placebo Aumolertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aumolertinib, Hansoh Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Aumolertinib, Hansoh Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, Hansoh Pharmaceutical, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/